VivoSeq
Other

Doxorubicin

0

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Doxorubicin is an early-stage landscape with 0 programs across 5 companies. The most active players are International Group of Endovascular Oncology, Bayer, Shenzhen Kangzhe Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

International Group of Endovascular Oncology

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalS

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

0 programs

PreclinicalCSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

0 programs

PreclinicalZ

Zhejiang Teruisi Pharmaceutical Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed12 · 48%
Active, not recruiting3 · 12%
Terminated3 · 12%
Withdrawn3 · 12%
Unknown status2 · 8%
Recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

25 trials

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
Recruiting·IInSightec·Phase 1/2·NCT05615623·10 enrolled
Bevacizumab/Doxorubicin/Radiation for Sarcoma
Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT01746238·14 enrolled
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Active, not recruiting·—·Phase 1·NCT04032964·2 enrolled
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Active, not recruiting·SSkinJect, Inc.·Phase 1/2·NCT04928222·25 enrolled
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Not yet recruiting·ZZhejiang Teruisi Pharmaceutical Inc.·Phase 1/2·NCT07035379·66 enrolled
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Completed·UUniversity Hospital Muenster·Phase 2·NCT01095926·101 enrolled
Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
Completed·SSeoul National University Hospital·Phase 2·NCT04224337·16 enrolled
Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
Completed·—·Phase 1·NCT02260544·49 enrolled
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Completed·Bayer logoBayer·Phase 1·NCT00562913·21 enrolled
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Completed·TTexas Tech University Health Sciences Center·Phase 4·NCT01537029·15 enrolled
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
Completed·UUniversity Hospital, Strasbourg, France·Phase 4·NCT03706157·10 enrolled
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Completed·VVirginia Commonwealth University·Phase 1·NCT01375699·26 enrolled
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Completed·—·Phase 2·NCT01670500·118 enrolled
A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
Completed·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·N/A·NCT04460820·32 enrolled
Pharmacogenetic of Doxorubicin in HCC.
Completed·—·N/A·NCT06313047·81 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)